CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Perampanel

Last Updated: September 13, 2018
Result type: Reports
Project Number: SR0458-000
Product Line: Common Drug Review

Generic Name: Perampanel

Brand Name: Fycompa

Manufacturer: Eisai Limited

Indications: Epilepsy, primary generalized tonic-clonic seizures

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: May 18, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions